Impact of antibiotic restrictions: The physician's perspective

Clinical Microbiology and Infection

Volumn 12, Issue SUPPL. 5, 2006, Pages 3-9

  Price, D ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Antibiotic resistance; Community acquired pneumonia; Mortality; Rational antibiotic prescribing; Review

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ANTIGEN; BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; ERYTHROMYCIN; MACROLIDE; PENICILLIN G; PLACEBO; SULFONAMIDE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIGEN DETECTION; BACTERIAL PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; CLINICAL OBSERVATION; CLINICAL PRACTICE; COMMUNITY ACQUIRED PNEUMONIA; GENERAL PRACTICE; HAEMOPHILUS INFLUENZAE; HEALTH CARE PLANNING; HIGH RISK PATIENT; HUMAN; LEGIONELLA; LOWER RESPIRATORY TRACT INFECTION; MEDICAL RESEARCH; MICROBIOLOGICAL EXAMINATION; MORAXELLA CATARRHALIS; MORTALITY; MYCOPLASMA PNEUMONIAE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT SELECTION; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; UNITED KINGDOM;

EID: 33745276516     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01525.x     Document Type: Review

References (30)

1. World Health Organization. The World Health Report 2002 -Reducing risks, promoting healthy life. Available at: http://www.who.int/whr/2002/en/ [Published: 2002; accessed: 4 January 2006].
2. Hoyert D, Kung H, Smith B. Deaths: Preliminary data for 2003. Natl Vital Stat Rep 2005; 53: 1-48.
3. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
4. Niederman MS, Mandell LA, Anzueto A et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-1754.
5. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-837.
6. Jackson ML, Neuzil KM, Thompson WW et al. The burden of community-acquired pneumonia in seniors: Results of a population-based study. Clin Infect Dis 2004; 39: 1642-1650.
7. Fine MJ, Smith MA, Carson CA et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275: 134-141.
8. Rello J, Rodriguez R, Jubert P, Alvarez B. Severe community-acquired pneumonia in the elderly: Epidemiology and prognosis. Study Group for Severe Community-Acquired Pneumonia. Clin Infect Dis 1996; 23: 723-728.
9. Greenberg SB. Viral pneumonia. Infect Dis Clin North Am 1991; 5: 603-621.
10. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN. The Alexander Project 1998-2000: Susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-246.
11. Garau J. Why do we need to eradicate pathogens in respiratory tract infections? Int J Infect Dis 2003; 7 (Suppl. 1): S5-S12.
12. Feikin DR, Schuchat A, Kolczak M et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90: 223-229.
13. Perez-Trallero E, Marimon JM, Iglesias L, Larruskain J. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg Infect Dis 2003; 9: 1159-1162.
14. Scheld WM. Maintaining fluoroquinolone class efficacy: Review of influencing factors. Emerg Infect Dis 2003; 9: 1-9.
15. Evans GM, Gaisford WF. Treatment of pneumonia with 2-(p-aminobenzenesulphonamido) pyridine. Lancet 1938; ii: 14-19.
16. Taylor SN, Sanders CV. Unusual manifestations of invasive pneumococcal infection. Am J Med 1999; 107: 12S-27S.
17. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342: 1878-1886.
18. Concato J, Shah N, Horwitz RI. Randomized controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-1892.
19. Felmingham D, Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens - findings of the Alexander Project 1992-1996. J Chemother 1999; 11 (Suppl. 1): 5-21.
20. House of Lords. Science and Technology - Seventh Report. Available at: http://www.parliament.the-stationery-office.co.uk/pa/ld199798/ldselect/ ldsctech/081vii/st0701.htm [Published: 1998; accessed: 4 January 2006].
21. Prescription Pricing Authority. PACT centre pages - antibacterial impact: The Prescription Pricing Authority Newsletter. Available at: http://www.ppa.org.uk/pdfs/imPACT/imPACTjune2001.pdf [Published: June 2001; accessed: 4 January 2006].
22. Price DB, Honeybourne D, Little P et al. Community-acquired pneumonia mortality: A potential link to antibiotic prescribing trends in general practice. Respir Med 2004; 98: 17-24.
23. Majeed A, Williams S, Jarman B, Aylin P. Prescribing of antibiotics and admissions for respiratory tract infections in England. Br Med J 2004; 329: 879.
24. Little P, Watson L, Morgan S, Williamson I. Antibiotic prescribing and admissions with major suppurative complications of respiratory tract infections: A data linkage study. Br J Gen Pract 2002; 52: 187-190, 193.
25. Bronzwaer SL, Cars O, Buchholz U et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002; 8: 278-282.
26. Almirall J, Bolibar I, Toran P et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004; 125: 1335-1342.
27. Castro-Guardiola A, Armengou-Arxe A, Viejo-Rodriguez A, Penarroja-Matutano G, Garcia-Bragado F. Differential diagnosis between community-acquired pneumonia and non-pneumonia diseases of the chest in the emergency ward. Eur J Intern Med 2000; 11: 334-339.
28. Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: Correlation with etiology and prognosis. Infection 2000; 28: 68-73.
29. Garcia Vazquez E, Martinez JA, Mensa J et al. C-reactive protein levels in community-acquired pneumonia. Eur Respir J 2003; 21: 702-705.
30. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-3143.